Reversible ventricular arrythmia induced by dasatinib

Hervé Spechbach; Philippe Morel; Kuntheavy Ing Lorenzini; Marie Besson; Laurent Gétaz; Henri Sunthorn; Yves Chalandon

doi:10.1002/ccr3.5

Reversible ventricular arrythmia induced by dasatinib

Clin Case Rep. 2013 Oct;1(1):20-5. doi: 10.1002/ccr3.5. Epub 2013 Jul 31.

Authors

Hervé Spechbach¹, Philippe Morel¹, Kuntheavy Ing Lorenzini², Marie Besson², Laurent Gétaz³, Henri Sunthorn⁴, Yves Chalandon⁵

Affiliations

¹ Department of Internal Medicine, University of Geneva Hospitals Geneva, Switzerland.
² Department of Clinical Pharmacology and Toxicology and Regional Pharmacovigilance Centre, University of Geneva Hospitals Geneva, Switzerland.
³ Prison Medicine Unit Department of Community Medicine, University of Geneva Hospitals Geneva, Switzerland.
⁴ Department of Cardiology, University of Geneva Hospitals Geneva, Switzerland.
⁵ Department of Haematology, University of Geneva Hospitals Geneva, Switzerland.

PMID: 25356203
PMCID: PMC4184536
DOI: 10.1002/ccr3.5

Abstract

Ventricular arrhythmias induced by dasatinib are rare events, but physicians in charge of chronic myeloid leukemia patients should be aware of such potential complications and the need for regular ECG controls during treatment with tyrosine kinase inhibitors.

Keywords: Adverse drug reaction; BCR-ABL (breakpoint cluster region-abelson); chronic myeloid leukaemia; dasatinib; ventricular arrhythmia.